New hope for PAH patients: experimental drug enters phase 2 trial

NCT ID NCT07318597

First seen Jan 07, 2026 · Last updated May 14, 2026 · Updated 21 times

Summary

This study tests an experimental drug called REGN13335 in 99 adults with pulmonary arterial hypertension (PAH), a condition where high blood pressure in the lungs makes the heart work harder. Participants will receive either the drug or a placebo alongside their usual PAH medications. The goal is to see if REGN13335 can safely lower lung blood vessel resistance and improve heart function.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION (PAH) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Imperial College Healthcare NHS Trust, Hammersmith Hospital

    RECRUITING

    London, W12 0HS, United Kingdom

  • Seoul National University Hospital

    RECRUITING

    Seoul, 03080, South Korea

  • University of Colorado Denver

    RECRUITING

    Aurora, Colorado, 80045, United States

Conditions

Explore the condition pages connected to this study.